Navigation Links
Biosense Webster Introduces the THERMOCOOL(R) SF Irrigated Catheter in the European Union
Date:5/13/2010

WATERLOO, Belgium, May 13, 2010 /PRNewswire/ --

- State-of-the-Art Irrigated Ablation Catheter Offers a Unique Design and Industry Leading Cooling Efficiency

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today the completion of the first clinical cases with the new THERMOCOOL(R) SF Irrigated Ablation catheter in the European Union, following recent CE Mark approval. The THERMOCOOL(R) SF catheter is the most advanced Biosense Webster irrigated ablation catheter for use by electrophysiologists in treating cardiac arrhythmias, commonly referred to as irregular heart rhythms.

The THERMOCOOL (R) SF Irrigated catheter is the next generation in irrigated ablation catheters and builds upon the industry leading THERMOCOOL(R) irrigated catheter platform. The THERMOCOOL (R) SF catheter's unique design and porous tip technology provides EPs with uniform cooling across the entire catheter tip and allows efficient cooling at half the flow rate.

"The THERMOCOOL(R) SF Irrigated Catheter is the latest advancement in irrigated ablation catheter design with its groundbreaking and unique porous tip technology," said Shlomi Nachman, Worldwide President, Biosense Webster, Inc. "This innovation further builds upon our clear leadership position in the electrophysiology market and reinforces our long-standing commitment to electrophysiologists and their patients. "We are extremely pleased this exciting new product will be launched throughout the European Union over the coming months."

Unlike competitive irrigated technologies which offer localized cooling, the cutting edge catheter design and breakthrough porous tip technology of the THERMOCOOL(R) SF catheter allow for uniform cooling of the entire catheter tip when ablating. This in turn allows for efficient fluid delivery within the catheter itself and allows heat to dissipate across the entire catheter tip. As a result, cooling efficiency is increased and the flow rate is reduced.

Prof. Gerd Hindricks of the Heart Center at the University of Leipzig Hospital commented on his recent experience with Biosense Webster's new catheter platform."The THERMOCOOL (R) SF catheter is a new and exciting technology that represents a significant advancement in irrigated ablation for electrophysiologists." "I have been extremely impressed with the features & capabilities of the THERMOCOOL (R) SF catheter." "My first clinical experience indicates that due to the strategic placement of the holes around the entire surface area of the tip, cooling efficiency and lesion induction may be improved to complete Atrial Fibrillation ablation procedures in a safe, effective, and timely manner."

"Procedure time & safety concerns are consistently cited by EPs as the most significant barrier to increased use of ablation therapy to treat cardiac arrhythmias," added Nachman. "All of our products are being developed with the aim of addressing these concerns."

The ThermoCool SF(R) catheter is the latest in a series of innovations from Biosense Webster. In recent months, the company has launched its ground-breaking new 3D mapping platform, the CARTO(TM) 3 System in Europe and the NAVISTAR (R) & Celsius(R) RMT THERMOCOOL(R) Catheters globally.

The NAVISTAR(R) THERMOCOOL(R) Catheters, including its bidirectional EZ STEER(R) Catheter platform, remains the first and only US Food & Drug Administration approved catheter for the safe and effective treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with the CARTO(R) System.

About Biosense Webster, Inc.

Biosense Webster, Inc., a Johnson & Johnson company, pioneered electrophysiology diagnostic catheters more than 30 years ago and continues to lead the industry as an innovative provider of advanced diagnostic, therapeutic and mapping tools. As the leader in navigation systems and ablation therapy, Biosense Webster, Inc.'s technology includes the largest installed base of navigation systems worldwide in leading hospitals and teaching institutions. With its proprietary products the company is changing the way electrophysiologists diagnose and treat arrhythmias.

    Contact: Name:
    Ulrike Domany,
    Director Public Affairs & Communication EMEA,
    (o) +43-1-36025-396,
    (m) +43-664-83-504-83.



'/>"/>
SOURCE Biosense Webster, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. Dr. Dello Russo Introduces the New EYE-Q Lasik
3. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
4. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
5. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
6. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. Siemens Introduces New Standard of Care for Breast Ultrasound
9. Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimers Treatments
10. Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
11. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):